Skip to content
GLP1-US
Prices checked Wegovy pill $149 Wegovy pen $349 Zepbound $299–449 Foundayo from $149 Ozempic $349 Medicare Bridge $50 Compounded sema $175 All prices →

GLP-1 coverage by state · 50 states and DC · state documents checked Oct 17 to Oct 22, 2026

Which States Cover Wegovy and Zepbound in Medicaid? All 50 States and DC

As of October 2026, 10 of 50 states and DC cover GLP-1s for weight loss in Medicaid: 8 at the usual BMI 30 (or 27 with a condition) bar and 2 only at about BMI 40 (Michigan, Virginia). The other 41 do not; 8 of them ended coverage in 2025-2026, and Indiana has announced coverage without a start date. Most still pay for Wegovy for heart risk or MASH and Zepbound for sleep apnea.

  • Covers weight loss: 8
  • Narrow, BMI 40+: MI, VA (2)
  • No weight-loss coverage: 41
  • Ended 2025-2026: CA, PA, CT, MA, NH, SC, UT, RI (8)
  • Announced, not started: IN (1)
  • Medicare Bridge: $50/mo in every state

We may earn a commission when you click links to providers, and partner relationships can affect which providers we feature and their order. Advertiser Disclosure

By GLP1-US Editorial TeamUpdated
Filter by Medicaid weight-loss coverage

Diabetes (Ozempic, Mounjaro) and heart-risk or sleep-apnea uses have separate rules; see the table.

01 State table

Medicaid GLP-1 Coverage by State: All 50 States and DC

Every row below comes from the state's own drug list, prior authorization (PA) criteria or Medicaid bulletin, read between October 17 and October 22, 2026. "Indication only" means the state pays for Wegovy or Zepbound when the diagnosis is heart disease, MASH (liver disease) or obstructive sleep apnea, never for weight loss alone. In every state, your prescriber files the PA; you cannot file it yourself.

StateMedicaid weight-loss coverageWegovy for heart risk / MASHZepbound for sleep apneaOzempic / Mounjaro (type 2 diabetes)2025-2026 changeState employee planProviders serving the stateGuide
North CarolinaYes, prior approval: BMI 30+, or 27+ with a weight-related condition; keep 5% off to renewCovered (stayed covered during the 2025 cut)Covered, moderate to severe OSAOzempic pen and Mounjaro preferredCut Oct 1, 2025; reinstated Dec 12, 2025; Zepbound vials removed Sep 4, 2026No weight-loss GLP-1s since Apr 1, 2024 (State Health Plan)9Open guide
TennesseeYes, PA: BMI above 30, or above 27 with a condition; renew with 5% lossHeart: PA (BMI 27+)Not separately listedMounjaro, Ozempic preferred with PACoverage effective Jan 1, 2026 (Milliman); Wegovy, Zepbound preferred on the Oct 1, 2026 PDLNot confirmed in a public plan document8Open guide
MissouriYes, PA: Zepbound or Foundayo at BMI 30+, or 27+ with a conditionHeart: 45+, BMI 27+, no diabetes. MASH: F2 to F3. Not for weight lossPreferred for obesity (OSA counts as a condition)Ozempic and Mounjaro preferred for diabetesFoundayo added; criteria revised Apr 23, 2026Not confirmed in a public plan document8Open guide
WisconsinYes, PA: Zepbound or Foundayo at BMI 30+, or 27 to 30 with 2 risk factorsAdults: heart risk or MASH onlyNot separately listedCovered for type 2 diabetesWeight management class Jul 1, 2026; Saxenda and older drugs droppedFrom Jan 1, 2027: $200 copay9Open guide
MinnesotaYes, PA: BMI 30+, or 27+ with a condition; renew with 5% lossWegovy preferred in Weight Management AgentsZepbound non-preferredOzempic preferred; Mounjaro non-preferredIncretin class updated Apr 1, 2026Not confirmed in a public plan document8Open guide
KansasYes, PA: BMI 30+, or 27+ with a condition; renew with 5% at 12 weeks or 10% at 28 weeksWegovy under the general AOM criteria (BMI 40 gate removed Jun 1, 2025)Zepbound under the general AOM criteria, 28-week first approvalNot checked for this guideWegovy freed from the BMI 40 high-cost rule Jun 1, 2025Not confirmed in a public plan document9Open guide
MississippiYes, PA: BMI 30+, or 27 to 29 with a condition; renew with 5% lossWegovy preferred for weight loss (12+)Zepbound preferred for weight loss (18+)Not checked for this guideFoundayo listed in criteria effective Jul 1, 2026Not confirmed in a public plan document7Open guide
DelawareYes, PA: BMI 30+, or 27+ with a condition, plus a documented weight-related condition; keep 5% off to renewHeart: BMI 27 to 29.9 with CVD. MASH: F2 to F3, no BMI ruleOn the anti-obesity PA listNot checked for this guideState Plan comorbidity rule added Q1 2026; heart and MASH routes addedNot confirmed in a public plan document7Open guide
MichiganYes, narrow: BMI 40+, after 5 older drug types fail, only to avert bariatric surgeryHeart: BMI 27+ with established CVD, no BMI 40 rule. MASH: own criteriaOwn class and PA criteriaOzempic pen preferred; Mounjaro moves to preferred Nov 1, 2026BMI 40 rule from Jan 1, 2026 (MDHHS letter L 25-73, Dec 8, 2025)Not confirmed in a public plan document9Open guide
VirginiaYes, narrow: BMI above 40, or above 37 with a condition, after an older drug failsHeart and MASH: separate SA formsSeparate SA formCovered for type 2 diabetesWeight-loss SA form revised Apr 16, 2026COVA Care: Tier 3, $45 a month9Open guide
CaliforniaNo, ended Jan 1, 2026 (age 21+); under 21 case by caseHeart: PA. MASH: no PA since Apr 1, 2026 with the diagnosis codePA consideredCovered only with a type 2 diabetes diagnosis on fileMedi-Cal Rx ended weight-loss coverage Jan 1, 2026CalPERS HMOs (Blue Shield, Kaiser): BMI 40+ with PA; self-insured PPO: no9Open guide
TexasNo weight-loss route in the PA criteriaHeart: age 45+ with CVD. MASH: F2 to F3 fibrosis, injection onlyAHI 15+; 180 days, renew with 5% lossOzempic preferred with clinical PA; Mounjaro non-preferredPA criteria revised May 8, 2026; Wegovy 4 mg tablets added Aug 11, 2026ERS HealthSelect: obesity-only drugs excluded; Wegovy for heart risk with PA9Open guide
FloridaNo, weight control drugs excludedNo criteria publishedNo criteria publishedPreferred with PA: A1c 6.5%+ and a metformin trialNo change to weight-loss coverageWeight Management Program 2027: 2,000 places, applications Nov 2 to 6, 20269Open guide
New YorkNo, excluded by regulationHeart: BMI 40+, 2 attempts per lifetime. MASH: not listedBMI 40+, 2 attempts per lifetimeOzempic pen preferred; Mounjaro non-preferred, PACriteria in the NYRx list revised Sep 14, 2026Empire Plan: Wegovy and Zepbound preferred with PA (Jul 2026)10Open guide
PennsylvaniaNo, ended Jan 1, 2026Heart (BMI 27+) and MASH, non-preferred, after OzempicBMI 35+, last in the PA orderOzempic pen and tablets preferred; every GLP-1 needs PA; Mounjaro non-preferredBulletin Nov 24, 2025; coverage ended Jan 1, 2026; guidelines updated Mar 2, 2026PEBTF rules not public9Open guide
IllinoisNo, "anorectic drugs" excluded by ruleWegovy pen and pill: heart risk or MASH, non-preferredCovered for OSA only, non-preferredOzempic tablets preferred with PA; Ozempic pen and Mounjaro after a preferred GLP-1Wegovy and Zepbound added for these uses on the Oct 1, 2026 list; Rybelsus to Ozempic tablets (May 21, 2026)State law requires weight-loss injectables since Jul 1, 20249Open guide
OhioNo, obesity drugs excluded by ruleHeart (BMI 27+) or MASH, PA for 180 days; no Wegovy HD 7.2 mgNot on the drug list, no published pathOzempic: PA after 120 days on 3 preferred drugs; Mounjaro: A1C above 7% plus 120 days on OzempicWegovy heart and MASH criteria first listed Apr 1, 2026Weight-loss GLP-1s ended Jul 1, 2025; Virta program with partial reimbursement, capped at 2,5009Open guide
GeorgiaNo for adults; Saxenda ages 12 to 17 only (with a cholesterol diagnosis)Not on the drug listNot on the drug listPreferred with PA, A1c 6.5%+ (Mounjaro from age 10)PA rewrite Jul 1, 2026: A1c 7% to 6.5%, step therapy droppedSHBP covers weight-loss drugs with PA; 9amHealth optional since Oct 1, 20268Open guide
New JerseyNo, antiobesics excluded (N.J.A.C. 10:51)No state criteria publishedNo state criteria publishedCovered for type 2 diabetesNo change foundSHBP: Wegovy, Saxenda, Zepbound $45 per 30 days (2026)8Open guide
WashingtonNo, "not covered by Apple Health for weight loss"Heart (BMI 27+) and MASH: PA, no diabetesPA: BMI above 30, no diabetesHCA policy 27.17.00Wegovy policy updated Feb 1, 2026Not confirmed in a public plan document9Open guide
ArizonaNo, "medications used for weight loss treatment" excludedNot confirmedNot confirmedNot confirmed (AHCCCS drug list not reachable)No change foundNot confirmed in a public plan document9Open guide
MassachusettsNo, ended July 2026Heart (established CVD) and MASH with a new PAModerate to severe OSA with a new PADiabetes GLP-1s on the MassHealth Drug ListObesity coverage ended Jul 1, 2026; older PAs end-dated Jun 30Not confirmed in a public plan document9Open guide
IndianaNot yet: adult coverage announced Jul 30, 2026, start date not set; under 21 case by caseNot confirmedNot confirmedNot checked for this guideBALANCE model joined Jul 30, 2026 (Zepbound, Foundayo)Not confirmed in a public plan document9Open guide
MarylandNo, weight management excluded (COMAR 10.57.06.27A(12))Not confirmedNot confirmedLab-confirmed diabetes required; not for prediabetesNo change foundNot confirmed in a public plan document9Open guide
ColoradoNo, PA "solely for weight loss will not be approved"Heart: BMI 25+ with CVD, no type 2 diabetes. MASH: F2 to F3KwikPen preferred; BMI 30+, failed 6-month CPAP trialOzempic and Mounjaro preferred for type 2 diabetesGLP-1 class criteria effective Oct 1, 2026Not confirmed in a public plan document9Open guide
South CarolinaNo, ended Jan 1, 2026No route on the PDLNo route on the PDLOzempic, Trulicity preferred; Mounjaro non-preferredAdded Nov 1, 2024; ended Jan 1, 2026PEBA: weight-loss medications excluded7Open guide
AlabamaNo; Zepbound non-covered for weight reduction without sleep apneaWegovy non-preferred, PA (use not stated on the PDL)Preferred with clinical criteria, OSA with obesity onlyOzempic and Mounjaro preferred with clinical criteriaMounjaro added as preferred Jan 1, 2026Not confirmed in a public plan document7Open guide
LouisianaNo; Zepbound criteria written for sleep apnea onlyNot confirmed (LDH criteria not reachable)AHI 15+ within 12 months, BMI 30+, no diabetesNot checked for this guideSB 433 (2026) proposed coverage from Jan 1, 2027Not confirmed in a public plan document6Open guide
KentuckyNo, Wegovy for weight loss excludedHeart: 45+, BMI 27+, on heart drugs, no diabetes. MASH: F2 to F3AHI 15+, BMI 30+, 3 months PAP firstNot checked for this guideWegovy criteria updated Jan 3, 2026Not confirmed in a public plan document9Open guide
OregonNo, drugs "only for weight management" not coveredHeart and MASH: PAPA; Zepbound pens preferredTrulicity, Victoza preferred; Ozempic, Mounjaro non-preferredWeight Management Drugs criteria implemented Mar 1, 2026Not confirmed in a public plan document9Open guide
OklahomaNo, obesity drugs not covered (OAC 317:30-5-72.1)Heart (age 45+, A1C under 6.5%) and MASH: PAPA: AHI 15+Covered for type 2 diabetes2026 criteria; PA forms revised Sep 2026Not confirmed in a public plan document8Open guide
ConnecticutNo, ended for weight loss in 2025 (reported; state bulletin not reachable)Reported: heart and MASH routes (bulletin not reachable)Reported: OSA route (bulletin not reachable)Covered for type 2 diabetesWeight-loss coverage cut in 2025Not confirmed in a public plan document9Open guide
UtahNo, pilot ended Jun 30, 2026Heart and MASH: PAPA: 70% CPAP adherencePer the Medicaid PDLWeight-loss pilot Jul 1, 2025 to Jun 30, 2026 (fee-for-service)PEHP: 50% back, up to $150/mo, from Jul 1, 20268Open guide
IowaNo, weight loss excluded (IAC 441-78.2(4))Heart: BMI 27+ with CVD, no diabetes. MASH: F2 to F3AHI 15+ within 3 years, BMI 30+Separate diabetes PA criteriaNon-diabetes PA form revised Jan 2026Not confirmed in a public plan document8Open guide
NevadaNo, weight-management agents excluded (MSM 1203)Heart (cardiologist, no diabetes) and MASH: PAPA: CPAP compliance, BMI above 30Mounjaro and Ozempic tablets preferred with PA from Aug 1, 2026Single PDL Jan 1, 2026; Mounjaro preferred Aug 1, 2026PEBP: diabetes indication required (May 2026 board)9Open guide
ArkansasNo, "does not cover medications for weight loss"Heart: BMI 27+ with established CVD. MASH: F2 to F3. Manual PAAHI 15+, BMI 30+ with a condition, 6 months CPAP firstNon-preferred with PA; Trulicity, Victoza preferredWegovy tablets added to heart criteria (memo May 13, 2026)Not confirmed in a public plan document6Open guide
New MexicoNo, Wegovy, Zepbound, Saxenda listed "not covered"No state criteria publishedNo state criteria publishedThrough Turquoise Care plan formulariesNo change foundNot confirmed in a public plan document9Open guide
IdahoNo, per coverage trackers (state PDL not reachable)Not confirmedNot confirmedCovered for type 2 diabetes (trackers)State employee plan ended weight-loss drugs Nov 1, 2025All weight-loss drugs dropped Nov 1, 20259Open guide
NebraskaNo, not on the Oct 1, 2026 PDLNo published criteriaNo published criteriaOzempic preferred after metformin; Mounjaro non-preferredNo change foundNot covered, also not for sleep apnea (DAS FAQ)9Open guide
West VirginiaNo, weight loss a benefit exclusionHeart (specialist, A1C 6.5% or less) and MASH: PAPA since Jul 1, 2025Covered for type 2 diabetesWegovy criteria effective Jan 1, 2026PEIA: diabetes only since Mar 15, 20247Open guide
HawaiiNo, "drugs for weight loss... are not covered" (AlohaCare QUEST)No published criteria foundNo published criteria foundPlan formulary, not checked2026 bills HB 2456, SB 3195 proposed coverageNot confirmed in a public plan document7Open guide
New HampshireNo, ended Jan 1, 2026Covered with PA (separate MACE and MASH criteria)Covered for severe OSAType 2 diabetes after an oral drug trialWeight-loss coverage ended Jan 1, 2026 (notice Oct 9, 2025)Not confirmed in a public plan document9Open guide
MaineNo, "weight loss drugs are not covered"Heart or MASH with BMI over 27, not for weight loss onlyBMI 30+, AHI 15+ within 3 years, CPAP 90 days firstRybelsus, Trulicity, Victoza preferred; Ozempic non-preferredNo change foundNot confirmed in a public plan document9Open guide
MontanaNo, no weight-loss class on the PDLHeart (BMI above 27, cardiac specialist) and MASH: PAPA: AHI 15+, 6 months of CPAP firstOzempic preferred; Mounjaro non-preferred (2 preferred drugs, 6 months each)Wegovy PA form updated Aug 2026Weight-reduction drugs excluded (2026 plan document)9Open guide
Rhode IslandNo, ended Oct 1, 2026No route on the PDLNo route on the PDLOzempic preferred; Mounjaro non-preferredWeight management class removed Oct 1, 2026Anchor Plan excludes weight-loss drugs7Open guide
South DakotaNo, "No coverage for weight loss"Wegovy listed for MACE or MASH onlyZepbound listed for OSA onlyListed for type 2 diabetesNo change foundNot confirmed in a public plan document8Open guide
North DakotaNo; obesity covered only with phentermine-type drugsSemaglutide PA: age 55 to 74, BMI 27 to 34.9; MASH PASemaglutide or tirzepatide PA after 6 months of CPAPCovered for type 2 diabetes; Ozempic also for antipsychotic weight gainManual v2026.7, Oct 1, 2026NDPERS: no GLP-1 for weight loss8Open guide
AlaskaNo, obesity drugs excluded by 7 AAC 120.112Wegovy tablets on the PA list since Dec 23, 2025 (2 failed therapies)No published criteria foundOzempic no PA; Mounjaro PA after 2 failed therapiesWegovy tablets added to the PA list Dec 23, 2025Not confirmed in a public plan document7Open guide
District of ColumbiaNo, anti-obesity drugs excludedNo criteria publishedNo criteria publishedOn the PDLNo change foundNot confirmed in a public plan document4Open guide
VermontNo, weight-loss drugs excludedWegovy preferred for heart risk or MASHZepbound preferred after criteriaCovered for type 2 diabetes after criteriaPDL of Oct 2, 2026Not confirmed in a public plan document8Open guide
WyomingNo, no weight-loss class on the PDLWegovy: MASH; heart per separate criteria chartPA: AHI above 15Preferred after a metformin trialNo change foundEGI: covered with a CVS weight program since Jan 1, 20269Open guide

Sources: each state's PDL, PA criteria and bulletins listed in References; provider counts from each provider's own site (state lists re-read Oct 23, 2026). "Providers serving the state" counts online programs whose own page states they serve that state. Rows for the 20 states added on October 22, 2026 (Alabama to Missouri) were checked that day; where a state document could not be reached, the row and the state guide say so. Rows for Montana to Wyoming and the District of Columbia were checked on October 22, 2026. Every provider count includes Found and MEDvidi only where those programs' own state lists name the state (re-read Oct 23, 2026).

The split is about diagnosis, not drug. Most states that refuse weight-loss coverage still pay for Wegovy to cut heart-event risk or treat MASH, and for Zepbound for obstructive sleep apnea, each with prior authorization. Every state covers GLP-1s for type 2 diabetes, but prescribed only for weight loss they fall under the same exclusions. National background: Medicaid coverage of weight loss shots.

02 Timeline

What Changed in 2025-2026

Between July 2025 and October 2026, eight Medicaid programs ended weight-loss coverage, North Carolina ended and restored it, and Tennessee and Wisconsin added it. Each step is dated from the state's own document where one could be read.

  1. Jul 1, 2025

    OH (state employees). The State of Ohio plan stops covering GLP-1s for weight loss; a Virta program with partial reimbursement opens Oct 7, 2025.

  2. Oct 1, 2025

    NC. NC Medicaid ends weight-loss coverage, citing state funding shortfalls.

  3. Oct 9, 2025

    NH. New Hampshire tells providers weight-loss GLP-1s end on Jan 1, 2026.

  4. Oct 21, 2025

    CA. Medi-Cal Rx announces GLP-1s for weight loss will not be a covered benefit.

  5. Nov 24, 2025

    PA. DHS bulletin ends obesity coverage for every GLP-1 and moves all GLP-1s into one PA class.

  6. Dec 8, 2025

    MI. MDHHS letter L 25-73 sets the BMI 40 rule for obesity GLP-1s.

  7. Dec 12, 2025

    NC. Weight-loss coverage reinstated, with the criteria of Sept 30, 2025.

  8. Jan 1, 2026

    CA, PA, MI. California and Pennsylvania stop paying for weight-loss GLP-1s; Michigan's BMI 40 rule takes effect. New Hampshire and South Carolina also end weight-loss coverage; TennCare coverage takes effect (Milliman).

  9. Apr 1, 2026

    CA, OH. Medi-Cal Rx drops PA for Wegovy for MASH when the diagnosis code is on the claim; Ohio first lists Wegovy for heart risk and MASH.

  10. Jun 30, 2026

    UT. Utah's one-year Medicaid weight-loss pilot ends; PEHP opens a GLP-1 reimbursement option for state employees on Jul 1.

  11. Jul 1, 2026

    GA, all states. Georgia lowers the Ozempic and Mounjaro A1c bar to 6.5%; the Medicare GLP-1 Bridge starts nationwide. Wisconsin adds Zepbound and Foundayo as preferred weight-loss drugs and drops Saxenda.

  12. Oct 1, 2026

    IL, GA. Illinois lists Wegovy (heart, MASH) and Zepbound (sleep apnea); Georgia's state plan makes 9amHealth optional. Rhode Island removes its weight management class.

  13. Nov 1, 2026

    MI. Mounjaro becomes preferred for diabetes; Foundayo is added as non-preferred for obesity.

03 Medicare

Medicare Is the Same in Every State

The Medicare GLP-1 Bridge is a federal CMS program, so none of its rules change at a state line. You need Part D (or a Medicare Advantage plan with drug coverage), a qualifying BMI tier and a prior authorization from your prescriber.

$50/mo
copay per fill
Jul 1, 2026 to Dec 31, 2027
program window
Covered
Wegovy (pen, HD and pill), Zepbound KwikPen only, Foundayo
Not covered
Ozempic, Mounjaro, Zepbound vials

BMI tiers (BMI at the start of GLP-1 therapy): 35 or higher; 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension or chronic kidney disease stage 3a or higher; 27 or higher with prediabetes, a prior heart attack, a prior stroke or symptomatic peripheral artery disease. Most Medicaid programs in the table set a higher bar for weight loss, or none at all, so people with both Medicare and Medicaid should ask which benefit pays first. Steps: Medicare GLP-1 Bridge.

Free Medicare counseling in each state (SHIP), with the state program's own name and phone line from the national SHIP directory (shiphelp.org, read Oct 22 and 23, 2026):

StateSHIP program
AlabamaSenior Health Insurance Program (SHIP), 800-243-5463
AlaskaSenior Health Insurance Program (SHIP), 800-478-6065
ArizonaArizona State Health Insurance Assistance Program (SHIP), 800-432-4040
ArkansasSenior Health Insurance Information Program (SHIIP), 800-224-6330
CaliforniaCalifornia Health Insurance Counseling and Advocacy Program (HICAP), 800-434-0222
ColoradoState Health Insurance Assistance Program (SHIP), 888-696-7213
ConnecticutConnecticut's Program for Health Insurance Assistance, Outreach, Information and Referral, Counseling, Eligibility Screening (CHOICES), 800-994-9422
DelawareDelaware Medicare Assistance Bureau, 800-336-9500
District of ColumbiaDC State Health Insurance Assistance Program (SHIP), 202-727-8370
FloridaServing Health Insurance Needs of Elders (SHINE), 800-963-5337
GeorgiaGeorgia State Health Insurance Assistance Program (GeorgiaCares), 866-552-4464, option 4
HawaiiHawaii State Health Insurance Assistance Program (SHIP), 888-875-9229
IdahoSenior Health Insurance Benefits Advisors (SHIBA), 800-247-4422
IllinoisSenior Health Insurance Program (SHIP), 800-252-8966
IndianaState Health Insurance Assistance Program (SHIP), 800-452-4800
IowaSenior Health Insurance Information Program (SHIIP), 800-351-4664
KansasSenior Health Insurance Counseling for Kansas (SHICK), 800-860-5260
KentuckyState Health Insurance Assistance Program (SHIP), 877-293-7447
LouisianaSenior Health Insurance Information Program (SHIIP), 800-259-5300
MaineMaine State Health Insurance Assistance Program (SHIP), 800-262-2232
MarylandState Health Insurance Assistance Program (SHIP), 800-243-3425
MassachusettsServing Health Insurance Needs of Everyone (SHINE), 800-243-4636
MichiganMichigan State Health Insurance Assistance Program (SHIP), 800-803-7174
MinnesotaMinnesota Aging Pathways, 800-333-2433
MississippiState Health Insurance Assistance Program (SHIP), 844-822-4622
MissouriMissouri State Health Insurance Assistance Program (SHIP), 800-390-3330
MontanaMontana State Health Insurance Assistance Program (SHIP), 406-444-4077
NebraskaNebraska SHIP, 800-234-7119
NevadaNevada Medicare Assistance Program (MAP), 800-307-4444
New HampshireNew Hampshire State Health Insurance Assistance Program (SHIP) ServiceLink Resource Center, 866-634-9412
New JerseyState Health Insurance Assistance Program (SHIP), 800-792-8820
New MexicoNew Mexico ADRC State Health Insurance Assistance Program (SHIP), 800-432-2080
New YorkHealth Insurance Information, Counseling and Assistance (HIICAP), 800-701-0501
North CarolinaSeniors' Health Insurance Information Program (SHIIP), 855-408-1212
North DakotaState Health Insurance Counseling Program (SHIC), 888-575-6611
OhioOhio Senior Health Insurance Information Program (OSHIIP), 800-686-1578
OklahomaSenior Health Insurance Counseling Program (SHIP), 800-763-2828
OregonSenior Health Insurance Benefits Assistance (SHIBA), 800-722-4134
PennsylvaniaPA MEDI (Pennsylvania Medicare Education and Decision Insight), 800-783-7067
Rhode IslandSenior Health Insurance Program (SHIP), 888-884-8721
South CarolinaState Health Insurance Assistance Program (SHIP), 800-868-9095
South DakotaSenior Health Information and Insurance Education (SHIINE), 888-854-5321
TennesseeState Health Insurance Assistance Program (SHIP), 877-801-0044
TexasHealth Information, Counseling, and Advocacy Program (HICAP), 800-252-9240
UtahSenior Health Insurance Information Program (SHIP), 800-541-7735
VermontState Health Insurance Assistance Program (SHIP), 800-642-5119
VirginiaVirginia Insurance Counseling & Assistance Program (VICAP), 800-552-3402
WashingtonStatewide Health Insurance Benefits Advisors (SHIBA), 800-562-6900
West VirginiaState Health Insurance Assistance Program (SHIP), 877-987-4463
WisconsinState Health Insurance Assistance Program (SHIP), 800-242-1060
WyomingState Health Insurance Assistance Program (SHIP), 800-856-4398

04 Self-pay

Self-Pay Prices Are National

No state sets its own GLP-1 price, so a Medicaid denial anywhere leads to the same manufacturer self-pay prices, as of October 2026.

DrugSelf-pay per monthChannel
Wegovy pill$149 (1.5 mg), $199 (4 mg), $299 (9 and 25 mg)NovoCare
Wegovy pen$199 for the first 2 fills (new patients, through Dec 31, 2026), then $349; Wegovy HD $399NovoCare
Zepbound vial or KwikPen$299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg) with a refill within 45 daysLillyDirect
Foundayofrom $149 (0.8 mg)LillyDirect

Medicaid cannot be billed for these, and manufacturer $25 savings cards exclude government insurance. Every channel, including TrumpRx and Costco: GLP-1 cost.

05 Next steps

If Medicaid Says No

  1. 1Check for a covered diagnosis. In most states without weight-loss coverage, Wegovy or Zepbound is still covered for heart disease, MASH or sleep apnea. Ask your prescriber whether one applies; never ask for a diagnosis you do not have.
  2. 2Send the records with the PA. States ask for earlier treatments with dates and results, labs and test results (a sleep study for sleep apnea, a fibrosis test for MASH). Some claims also need the diagnosis code on the prescription, as with Wegovy for MASH in California. Our BMI calculator gives the number most forms ask for.
  3. 3Ask for the denial reason in writing. Call your state's Medicaid member line or your managed care plan, and ask about an appeal or a State Fair Hearing if the denial stands. Each state guide lists the line.
  4. 4Under 21? Ask about EPSDT. California reviews weight-loss PA requests for members under 21 one by one under the federal EPSDT benefit, Oregon does the same, and one Pennsylvania plan says so too. Ask your plan in writing.
  5. 5Check Medicare and cash routes. If you also have Medicare, the $50 Bridge has a lower BMI bar than most Medicaid programs here. Otherwise, the lowest self-pay starting prices are the Wegovy pill and Foundayo, both from $149 a month.

Need a prescriber for steps 1 to 3? The hero visit link (PlushCare) covers it; check whether PlushCare accepts your coverage before booking.

06 FAQ

Medicaid GLP-1 Coverage by State: FAQ

Which states cover Wegovy in Medicaid for weight loss?
As of October 2026, 8 programs cover them at the usual bar of BMI 30, or 27 with a weight-related condition: North Carolina, Tennessee, Missouri, Wisconsin, Minnesota, Kansas, Mississippi, Delaware. Michigan (BMI 40+, after older drugs fail) and Virginia (BMI above 40, or above 37 with a condition, after an older drug fails) cover them narrowly. Indiana has announced coverage without a start date.
Which states cover Wegovy or Zepbound in Medicaid only for other conditions?
Most of the states without weight-loss coverage, including California, Texas, New York, Pennsylvania, Illinois, Ohio, Nevada, Oklahoma, Oregon, Washington, West Virginia, Vermont, Montana and Utah. They pay for Wegovy for heart-event risk (Ohio, Pennsylvania, Illinois, Texas and California also for MASH) and, except Ohio, Zepbound for obstructive sleep apnea, each with prior authorization. New York sets a BMI floor of 40 and allows two treatment attempts per lifetime.
Which states stopped Medicaid coverage of GLP-1s for weight loss?
In 2025-2026: California, Pennsylvania, New Hampshire and South Carolina on January 1, 2026; Utah when its pilot ended June 30, 2026; Massachusetts in July 2026; Rhode Island on October 1, 2026; Connecticut in 2025 (reported). Michigan narrowed coverage to BMI 40 or higher on January 1, 2026, and North Carolina ended it on October 1, 2025 and reinstated it on December 12, 2025. Tennessee and Wisconsin moved the other way and added coverage.
Does Medicaid cover Ozempic and Mounjaro in every state?
For type 2 diabetes, yes, in all 50 states and DC, with prior authorization or step rules that differ by state. Florida and Georgia require an A1c of 6.5% or higher; Ohio requires 120 days on three preferred diabetes drugs before Ozempic; Nebraska asks for a metformin trial first. Prescribed only for weight loss, they are not covered.
Is Medicare GLP-1 coverage different by state?
No. The Medicare GLP-1 Bridge is federal: $50 a month for Wegovy (pen, HD and pill), the Zepbound KwikPen and Foundayo from July 1, 2026 to December 31, 2027, with Part D, a qualifying BMI tier and a prior authorization. Each state's SHIP program gives free counseling on it.

07 By insurer

Not on Medicaid? Coverage by Insurer

Employer and Medicare plans follow the insurer's rules, not the state's Medicaid program. What each publishes, with dates: Medicare, Blue Cross Blue Shield, UnitedHealthcare, Aetna, Cigna and Kaiser Permanente. All payer types side by side: GLP-1 cost with insurance.

Medical Disclaimer

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed physician or qualified health provider with any questions about a medical condition or medication. Never disregard professional medical advice or delay seeking it because of something you have read on this website.

Checked against primary sources such as FDA labels, CMS and provider pages
Updated
How we check facts →

References

  1. Important Update: GLP-1s for Weight Loss Are Not a Covered Benefit, checked 2026-10-17; document dated Oct 21, 2025, DHCS Medi-Cal Rx
  2. GLP-1 Coverage Considerations, checked 2026-10-17; document dated Dec 12, 2025, updated Apr 6, 2026, DHCS Medi-Cal Rx
  3. Changes to GLP-1 Drug Coverage for Wegovy, checked 2026-10-17; document dated Apr 6, 2026, DHCS Medi-Cal Rx
  4. Agenda Item 8c, Senate Bill 1089 (Richardson), checked 2026-10-17; document dated Jun 17, 2026, CalPERS Board of Administration
  5. Clinical Criteria: Wegovy (Semaglutide), checked 2026-10-17; document dated Revised May 8, 2026, Texas Prior Authorization Program (Acentra Health for HHSC)
  6. Clinical Criteria: Zepbound (Tirzepatide), checked 2026-10-17; document dated Revised May 8, 2026, Texas Prior Authorization Program
  7. Clinical Criteria: GLP-1 Receptor Agonists, checked 2026-10-17; document dated Apr 3, 2026, Texas Prior Authorization Program
  8. Texas Medicaid Preferred Drug List, checked 2026-10-17; document dated Effective Jul 24, 2026, Texas HHSC
  9. HealthSelect of Texas Prescription Drug Program, Master Benefit Plan Document, checked 2026-10-17; document dated Effective Sep 1, 2024, ERS / Express Scripts
  10. Florida Medicaid Preferred Drug List, checked 2026-10-17; document dated Effective Oct 1, 2026, AHCA
  11. Prior Authorization Criteria: GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists, checked 2026-10-17; document dated Revised Jul 2, 2026, AHCA Pharmacy Policy
  12. Florida Medicaid Prescribed Drug Services Coverage Policy (Rule 59G-4.250, F.A.C.), checked 2026-10-17; document dated December 2017, AHCA
  13. Weight Management Program, checked 2026-10-17, Florida Department of Management Services, Division of State Group Insurance
  14. NYRx Preferred Drug List, checked 2026-10-17; document dated Revised Sep 14, 2026, NYRx, the Medicaid Drug Program (NYS DOH)
  15. 18 NYCRR 505.3(g), Limitations, checked 2026-10-17, New York Codes, Rules and Regulations
  16. 2026 Empire Plan Advanced Flexible Formulary Preferred Drug List, checked 2026-10-17; document dated July 2026, NY Department of Civil Service, NYSHIP
  17. Coverage Change and Prior Authorization of Obesity Treatment Agents, checked 2026-10-17; document dated Nov 24, 2025, effective Jan 1, 2026, PA DHS Medical Assistance Bulletin
  18. Prior Authorization of GLP-1 Receptor Agonists, checked 2026-10-17; document dated Mar 2, 2026, PA DHS Medical Assistance Bulletin
  19. Statewide Preferred Drug List, v16, checked 2026-10-17; document dated Effective January 2026, PA DHS
  20. GLP-1 Drugs to Treat Overweight and Obesity, Doc. No. 25-1777, checked 2026-10-17; document dated Dec 27, 2025, Pennsylvania Bulletin
  21. Illinois Medicaid Preferred Drug List, checked 2026-10-17; document dated Effective Oct 1, 2026, Illinois HFS
  22. Provider Notice (Rybelsus to Ozempic tablets), checked 2026-10-17; document dated May 21, 2026, Illinois HFS
  23. 89 Ill. Adm. Code 140.441, Pharmacy Services Not Covered, checked 2026-10-17, Illinois HFS rule
  24. State Employees Group Insurance Program Benefits Handbook (5 ILCS 375/6.11c), checked 2026-10-17; document dated Revised Oct 2025, Illinois CMS
  25. Unified Preferred Drug List, checked 2026-10-17; document dated Effective Oct 1, 2026, Ohio Department of Medicaid
  26. Unified Preferred Drug List, checked 2026-10-17; document dated Effective Apr 1, 2026, Ohio Department of Medicaid
  27. Ohio Admin. Code 5160-9-03, Pharmacy services: covered drugs and associated limitations, checked 2026-10-17; document dated Effective Feb 16, 2024, Ohio Department of Medicaid
  28. State of Ohio benefits package update (GLP-1 weight loss coverage ends Jul 1, 2025), checked 2026-10-17, Ohio DAS
  29. New weight loss benefit coming Oct. 7, checked 2026-10-17; document dated Sep 30, 2025, Ohio DAS
  30. Georgia Medicaid/PeachCare Preferred Drug List by drug class, checked 2026-10-17; document dated Effective Sep 1, 2026, Georgia DCH
  31. Antidiabetic Agents PA Summary, checked 2026-10-17; document dated Revised Jul 1, 2026, Georgia DCH
  32. Antihyperlipidemics, Other PA Summary (Xenical, Saxenda), checked 2026-10-17, Georgia DCH
  33. 9amHealth Weight Management Program, checked 2026-10-17, Georgia State Health Benefit Plan
  34. NC Medicaid to Change Coverage of GLP-1 Weight Management Medications, checked 2026-10-17; document dated Sep 5, 2025, NC Medicaid (NCDHHS)
  35. NC Medicaid to Reinstitute Coverage of GLP-1s for Weight Management, checked 2026-10-17; document dated Dec 19, 2025, NC Medicaid
  36. NC Medicaid Preferred Drug List, checked 2026-10-17; document dated Effective October 2026 (revised Sep 21, 2026), NC Medicaid
  37. Outpatient Pharmacy Prior Approval Criteria, GLP-1s for Weight Management, checked 2026-10-17; document dated Effective Aug 1, 2024, NC Medicaid
  38. Statement Regarding GLP-1 Coverage, checked 2026-10-17; document dated Mar 7, 2024, NC State Health Plan
  39. Numbered Letter L 25-73, Update of Pharmacy Drug Coverage for Treatment of Obesity, checked 2026-10-17; document dated Dec 8, 2025, MDHHS
  40. Michigan Preferred Drug List / Single PDL, checked 2026-10-17; document dated Effective Oct 1, 2026, MDHHS (Prime Therapeutics)
  41. Michigan Preferred Drug List changes, checked 2026-10-17; document dated Changes effective Nov 1, 2026, MDHHS (Prime Therapeutics)
  42. Michigan Medicaid Clinical and PDL Criteria, checked 2026-10-17; document dated Sep 2026, MDHHS (Prime Therapeutics)
  43. Medicare GLP-1 Bridge: information for Part D plans, checked 2026-10-17, CMS
  44. Weight Management Drugs PA criteria (implemented Mar 1, 2026), checked 2026-10-22, Oregon Health Authority
  45. TennCare Clinical Criteria, Oct 1, 2026, checked 2026-10-22, TennCare / OptumRx
  46. ForwardHealth Update 2026-15 (July 2026 PDL changes), checked 2026-10-22, Wisconsin DHS
  47. Service Authorization Form: Weight-Loss Management, rev. Apr 16, 2026, checked 2026-10-22, Virginia DMAS
  48. Change in Medicaid Coverage for GLP-1 Medications (Oct 9, 2025), checked 2026-10-22, NH DHHS
  49. Single Preferred Drug List, Oct 1, 2026, checked 2026-10-22, South Carolina DHHS
  50. PA form: GLP-1 Medications for Weight-related Comorbidities, Jun 1, 2026, checked 2026-10-22, Utah Medicaid
  51. Medicaid FFS Preferred Drug List, Oct 1, 2026, checked 2026-10-22, Rhode Island EOHHS
  52. Medicaid Services Manual Chapter 1200 (posted Oct 5, 2026), checked 2026-10-22, Nevada Health Authority
  53. Medical policy 61.25.20.AA-4: Wegovy, Feb 1, 2026, checked 2026-10-22, Washington HCA
  54. State Health Insurance Assistance Program directory, checked 2026-10-22 and 2026-10-23, SHIP Technical Assistance Center (shiphelp.org)